Off-Label Prescribing – A New Worry for the Pharmaceutical Industry

Off-Label Prescribing – A New Worry for the Pharmaceutical Industry

By Neil Grubert, market access specialist, analyst and author. EU Study on Off-Label Prescribing In recent years, the pharmaceutical industry has been concerned by the precedent set by the off-label use on purely economic grounds of Roche/Genentech/Chugai’s Avastin (bevacizumab) as a replacement for Roche/Novartis’s Lucentis (ranibizumab) in the management of wet age-related macular degeneration (AMD). The […]